Cargando…
Preclinical and post-treatment changes in the HCC-associated serum proteome
SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360589/ https://www.ncbi.nlm.nih.gov/pubmed/17060939 http://dx.doi.org/10.1038/sj.bjc.6603429 |
_version_ | 1782153086850039808 |
---|---|
author | Ward, D G Cheng, Y N'Kontchou, G Thar, T T Barget, N Wei, W Martin, A Beaugrand, M Johnson, P J |
author_facet | Ward, D G Cheng, Y N'Kontchou, G Thar, T T Barget, N Wei, W Martin, A Beaugrand, M Johnson, P J |
author_sort | Ward, D G |
collection | PubMed |
description | SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features would ‘return to normal’ following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the progression of underlying liver disease or from the emergence of precancerous lesions. β2-Microglobulin, a protein previously reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic feature (m/z 11720) in this study. |
format | Text |
id | pubmed-2360589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23605892009-09-10 Preclinical and post-treatment changes in the HCC-associated serum proteome Ward, D G Cheng, Y N'Kontchou, G Thar, T T Barget, N Wei, W Martin, A Beaugrand, M Johnson, P J Br J Cancer Molecular Diagnostics SELDI-based proteomic profiling of body fluids is currently in widespread use for cancer biomarker discovery. We have successfully used this technology for the diagnosis of hepatocellular carcinoma (HCC) in hepatitis C patients and now report its application to serial serum samples from 37 hepatitis C patients before development of HCC, with HCC and following radiofrequency ablation of the tumour. As with alpha-fetoprotein, an accepted biomarker for HCC, we hypothesised that HCC-associated proteomic features would ‘return to normal’ following successful treatment and the primary aim of our study was to test this hypothesis. Several SELDI peaks that changed significantly during HCC development were detected but they did not reverse following treatment. These data may be interpreted to suggest that the characteristic SELDI profile is not linearly related to tumour burden but may result from the progression of underlying liver disease or from the emergence of precancerous lesions. β2-Microglobulin, a protein previously reported to be markedly elevated in patients with HCV related HCC, was also the most significantly HCC associated proteomic feature (m/z 11720) in this study. Nature Publishing Group 2006-11-20 2006-10-24 /pmc/articles/PMC2360589/ /pubmed/17060939 http://dx.doi.org/10.1038/sj.bjc.6603429 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Molecular Diagnostics Ward, D G Cheng, Y N'Kontchou, G Thar, T T Barget, N Wei, W Martin, A Beaugrand, M Johnson, P J Preclinical and post-treatment changes in the HCC-associated serum proteome |
title | Preclinical and post-treatment changes in the HCC-associated serum proteome |
title_full | Preclinical and post-treatment changes in the HCC-associated serum proteome |
title_fullStr | Preclinical and post-treatment changes in the HCC-associated serum proteome |
title_full_unstemmed | Preclinical and post-treatment changes in the HCC-associated serum proteome |
title_short | Preclinical and post-treatment changes in the HCC-associated serum proteome |
title_sort | preclinical and post-treatment changes in the hcc-associated serum proteome |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360589/ https://www.ncbi.nlm.nih.gov/pubmed/17060939 http://dx.doi.org/10.1038/sj.bjc.6603429 |
work_keys_str_mv | AT warddg preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT chengy preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT nkontchoug preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT thartt preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT bargetn preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT weiw preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT martina preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT beaugrandm preclinicalandposttreatmentchangesinthehccassociatedserumproteome AT johnsonpj preclinicalandposttreatmentchangesinthehccassociatedserumproteome |